Table 1 Serial ctDNA Testing Categories.
From: Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors
| Â | Molecular response | Longitudinal monitoring | At-progression testing |
|---|---|---|---|
Definition | Assess changes in ctDNA in patients on treatment (~3–9 wks) vs. baseline | Assess increases and/or decreases in ctDNA over time | Use of ctDNA testing with clinical evidence of progressive disease |
Primary Use | Predict eventual outcomes/response to current therapy | Monitoring (correlation with patient disease status) | Interrogation of emergent resistance mutations, increase in VAF to correlate with clinical evidence of progressive disease |
Clinical Trigger | Start of initial or new therapy | Regular cadence (i.e. q3 months) OR when additional information needed to make clinical decision | Clinical signs of progression |
